



Notice of Annual General Meeting 2014

26th November, 2014 at 2.00 pm

To be held at:
BioSA Incubator Conference Centre
40-46 West Thebarton Road
Thebarton SA 5031

Notice of Annual General Meeting

Notice is hereby given that the Annual General Meeting of the shareholders of Ellex Medical Lasers Limited (the Company) will be held at BioSA Incubator Conference Centre, 40-46 West Thebarton Road, Thebarton, South Australia, at 2:00 pm (Adelaide time) on Wednesday 26 November 2014 for the purpose of transacting the following business.

Ordinary Business

1. Accounts & Reports

To receive and consider the financial statements of the Company and its controlled entities for the year ended 30 June 2014 and the related Directors' Reports, Directors' Declarations and Auditor's Report. The electronic copy of the 2014 Annual Report is available to download or view on the company website at the following address:

www.ellex.com/investors/investor-room/annual-reports.

The 2014 Annual Report has also been sent by post to those shareholders who have previously elected to receive a hard copy.

Resolution 2 – Re-election of Director

To consider and if thought fit, pass the following Ordinary Resolution:

“To re-elect Victor Previn as a director. Victor Previn retires by rotation in accordance with the Company's Constitution and, being eligible, offers himself for re-election.”

Resolution 3 – Adoption of Remuneration Report

To consider and if thought fit, pass the following Ordinary Resolution:

“To adopt the Remuneration Report as set out in the Directors' Report which forms part of the Annual Report for the year ended 30 June 2014”.

The resolution is advisory only and does not bind the Company or its directors. However, under the Corporations Act 2001, if 25% or more of votes that are cast are voted against the adoption of the remuneration report at two consecutive AGMs, shareholders will be required to vote at the second of those AGMs on a resolution (a “spill resolution”), that another meeting be held within 90 days at which all of the Company's directors must go up for re-election.

If there is 25% or more votes “against” the Resolution at this year's AGM, the Company will receive a “first strike”.

The Board will consider the outcome of the vote and comments made by shareholders on the remuneration report at the meeting when reviewing the Company's remuneration policies.

The Chairman of the meeting intends to vote undirected proxies in FAVOUR of this resolution.

A voting exclusion statement in relation to this resolution is set out on Page 3 of this Notice of Meeting.

Other Business

To deal with any other business that may be properly brought forward.

Shareholder Information

1. A shareholder entitled to attend and vote at this meeting is entitled to appoint not more than two proxies (who need not be shareholders of the Company) to attend and vote on a poll in the shareholder's place.
2. The appointment of two proxies should specify the percentage of voting rights or number of securities to be applied to each proxy and if not specified then each proxy may exercise half your votes with fractions disregarded. A single proxy exercises all voting rights.
3. Voting Exclusions for Resolution 3

In accordance with the Corporation Act, a vote must not be cast (in any capacity), and the Company will disregard any votes cast on Resolution 3 by any Key Management Personnel (which includes each of the Directors), the details of whose remuneration are included in the Remuneration Report, and any Closely Related Party of such Key Management Personnel.

However, a person described above may cast a vote on Resolution 3 if the vote is not cast on behalf of a person described above and either:

- (a) the person does so as proxy appointed in writing that specifies how the proxy is to vote on the proposed resolution; or
- (b) the Chair of the meeting is appointed as proxy and the appointment of the Chair does not specify the way in which the Chair is to vote and expressly authorises the Chair to exercise the proxy even though the resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.

Please note, in accordance with sections 250R(4) and 250R(5) of the Corporations Act, the Chair will not vote any undirected proxies in relation to a resolution unless the shareholder expressly authorises the Chair to vote in accordance with the Chair's stated voting intentions. Please note that if the Chair of the meeting is your proxy (or becomes your proxy by default), by completing the attached proxy form, you will expressly authorise the chair to exercise your proxy on Resolution 3 even though it is connected directly or indirectly with the remuneration of a member of Key Management Personnel for the Company, which includes the Chair.

If you appoint the Chair as your proxy, you can direct the Chair to vote for or against or abstain from voting on Resolution 3 by marking the appropriate box on the proxy form.

Alternatively, Shareholders can nominate as their proxy for the purpose of voting on Resolution 3, a proxy who is not a member of the Company's Key Management Personnel. That person would be permitted to vote undirected proxies.

4. The Company has determined in accordance with Corporations Regulation 7.11.37, that for the purpose of voting at the meeting, shares will be taken to be held by those who hold them at 7:00 pm (Adelaide time) on Monday 24 November 2014.

To record a valid vote, members will need to take the following steps:

Cast your vote online by visiting www.investorvote.com.au and following the instructions and information provided on the enclosed proxy form; or

Complete and lodge the Proxy Form (and the power of attorney or other authority, if any) under which it is signed, or a certified copy of it at:

- (a) the share registry of the Company, Computershare Investor Services Pty Limited, located at GPO Box 242, Melbourne VIC 3001, or by facsimile on 1800 783 447 (within Australia) or +61 3 9473 2555 (outside Australia); or
- (b) the registered office of the Company located at 82 Gilbert Street, Adelaide SA 5000, or by facsimile on (08) 8104 5231

no later than 48 hours before the time for the holding of the meeting.

Custodian voting – for Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions.

By order of the Board
Maria Maieli
Company Secretary
Adelaide

Dated: 13 October 2014

Explanatory Memorandum

Introduction

This Explanatory Memorandum has been prepared for the information of shareholders of Ellex Medical Lasers Limited (the Company) in connection with the business to be conducted at the Annual General Meeting to be held at 2:00 pm (Adelaide time) on Wednesday 26 November 2014

Financial Statements and Reports

The financial statements of the Company and its controlled entities for the year ended 30 June 2014 and the Directors' Report and Auditor's Report are set out in the Ellex Medical Lasers Limited Annual Report 2014.

Neither the Corporations Act nor the Company's Constitution requires a vote of shareholders to approve these Reports.

This item is intended to provide an opportunity for shareholders to raise questions of the Reports and on the performance of the Company generally. In addition, a reasonable opportunity will be given to members of the meeting to ask the Company's Auditor questions relevant to the conduct of the audit, the preparation and content of the Auditor's Report, the accounting policies adopted by the Company in relation to the preparation of the financial statements and the independence of the auditor in relation to the conduct of the audit.

Resolution 2 – Re-election of Director

Victor Previn, Executive Director

Victor Previn is 57 years old and was appointed a director on 16 July 2001 after the acquisition of Ellex Laser Systems. Victor Previn is a professional engineer and one of the original founders of Ellex. His career spans more than 30 years in the laser industry. Mr. Previn was responsible for developing and commercializing the technology platform that is now the core of Ellex's current production. He has spent more than 27 years in the ophthalmic laser industry travelling widely throughout Asia, Europe and the USA in a business development capacity.

Mr. Previn held the position of Managing Director from 2003 to 2005. In July of 2005, Mr. Previn was elected Chairman of the Ellex board of directors. He is also a member of the Audit & Risk Committee and the Remuneration Committee.

Board Recommendation

The Board (excluding V Previn because of his interest) unanimously recommends that shareholders vote in FAVOUR of the Resolution to re-elect Victor Previn as a Director.

The Chairman of the meeting intends to vote undirected proxies in FAVOUR of this resolution.

Resolution 3 – Remuneration Report

The Directors' Report, which forms part of the Annual Report for the year ended 30 June 2014, outlines the remuneration arrangements in place for Key Management Personnel (KMP) of the Company.

The Corporations Act 2001 requires that a resolution be put to shareholders each year to adopt the Remuneration Report. The vote on this resolution is advisory only and does not bind the directors or the Company, but the outcome could have consequences for the Board and the Company.

In 2011 new laws on executive remuneration were introduced, including the "two strike Rule". Under the two strike rule, if more than 25% of the votes cast on the resolution to adopt the Remuneration Report are "against" the resolution, the Company receives a "first strike". If this happens at the subsequent AGM, it will result in a "second strike".

The voting exclusion statement for this resolution is set out on Page 3 of this Notice of Meeting.

Board Recommendation

The Board unanimously recommends that shareholders vote in FAVOUR of this resolution.

The Chairman of the meeting intends to vote undirected proxies in FAVOUR of this resolution.

Glossary

In this Explanatory Memorandum and Notice of Annual General Meeting the following expressions have the following meanings unless stated otherwise or unless the context otherwise requires:

Board means the board of directors of the Company;

Closely Related Party of a member of the Key Management Personnel for an entity means:

- (a) a spouse or child of the member;
- (b) a child of the member's spouse;
- (c) a dependant of the member or of the member's spouse;
- (d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealings with the entity;
- (e) a company the member controls; or
- (f) a person prescribed as such by the Corporations Regulations 2001 (Cth);

Company means Ellex Medical Lasers Limited ACN 007 702 927;

Constitution means the existing constitution of the Company;

Corporations Act means Corporations Act 2001 (Cth);

Director means a director of the Company;

Key Management Personnel has the same meaning as in the accounting standards as defined in section 9 of the Corporations Act (so the term broadly includes those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any director, whether executive or otherwise, of the Company);

Meeting means the meeting of shareholders convened by the Notice;

Notice means the notice of meeting to which this Explanatory Memorandum is attached.

How to get to the AGM

Location

BioSA Incubator Conference Centre, 40-46 West Thebarton Road, Thebarton, South Australia

Telephone: +61 8 8152 9318

By Bus

Bus - 287 and 288 leave from North Terrace. Alight at bus stop 5B on West Thebarton Road.


By Tram

Tram - The Bonython Park tram stop is approximately 1km from the conference centre (10 minute walk).

By Taxi

Taxi – Adelaide Independent Taxi telephone located in the foyer of the BioSA conference centre building.

Parking details below:





Ellex Medical Lasers Limited

ABN 15 007 702 927

Lodge your vote:

Online:
www.investorvote.com.au

By Mail:
Computershare Investor Services Pty Limited
GPO Box 242 Melbourne
Victoria 3001 Australia

Alternatively you can fax your form to
(within Australia) 1800 783 447
(outside Australia) +61 3 9473 2555

For Intermediary Online subscribers only
(custodians) www.intermediaryonline.com

For all enquiries call:
(within Australia) 1300 556 161
(outside Australia) +61 3 9415 4000

Proxy Form

<p>Vote and view the annual report online</p> <ul style="list-style-type: none"> • Go to www.investorvote.com.au or scan the QR Code with your mobile device. • Follow the instructions on the secure website to vote. 	
<p>Your access information that you will need to vote:</p> <p>PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.</p>	

For your vote to be effective it must be received by 2:00pm (Adelaide time) on Monday 24 November 2014

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

Appointment of Proxy

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

Signing Instructions for Postal Forms

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

Attending the Meeting

Bring this form to assist registration. If a representative of a corporate securityholder or proxy is to attend the meeting you will need to provide the appropriate "Certificate of Appointment of Corporate Representative" prior to admission. A form of the certificate may be obtained from Computershare or online at www.investorcentre.com under the help tab, "Printable Forms".

Comments & Questions: If you have any comments or questions for the company, please write them on a separate sheet of paper and return with this form.

**GO ONLINE TO VOTE,
or turn over to complete the form** ➔

Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.

Proxy Form

Please mark to indicate your directions

STEP 1 Appoint a Proxy to Vote on Your Behalf

XX

I/We being a member/s of Ellex Medical Lasers Limited hereby appoint

the Chairman of the Meeting OR

PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the Meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Ellex Medical Lasers Limited to be held at **BioSA Incubator Conference Centre, 40-46 West Thebarton Road, Thebarton, South Australia at 2:00pm (Adelaide time) on Wednesday 26 November 2014** and at any adjournment or postponement of that Meeting.

Chairman authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chairman of the Meeting as my/our proxy (or the Chairman becomes my/our proxy by default), I/we expressly authorise the Chairman to exercise my/our proxy on **Item 3** (except where I/we have indicated a different voting intention below) even though **Item 3** is connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairman.

Important Note: If the Chairman of the Meeting is (or becomes) your proxy you can direct the Chairman to vote for or against or abstain from voting on **Item 3** by marking the appropriate box in step 2 below.

STEP 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

Ordinary Business

	For	Against	Abstain
2. Re-election of Victor Previn as a Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Adoption of Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chairman of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

SIGN Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Contact Name _____

Contact Daytime Telephone _____

Date / / _____



To Our Shareholders

The 2014 financial year saw a substantial improvement in the operating performance of the business and good steps forward in the positioning of our company as a significant global leader in the treatment of glaucoma and macular degeneration.

An operating profit before tax of \$1.3m was achieved compared with an operating profit of \$0.1m reported last year on the strength of a 26% growth in revenue. The growth in revenue was primarily attributable to the success of the launch of the Ellex Tango™, our SLT glaucoma treatment laser, into the USA and continued growth in Asia. The business also benefited from the fall in the value of the Australian dollar against the US\$ and the Euro. Favourable exchange rates contributed approximately 5% of the total revenue growth.

The success of the business in the USA with the Ellex Tango™ has been particularly pleasing from July 2013 when the expiry of a competitors patent enabled us to launch our world-leading Tango™ and Solo™ SLT lasers in the USA. With the expiration of the patent in the USA, we were able to translate our strong market position with SLT outside the USA into sales to US-based doctors. We augmented this position in the glaucoma treatment market with the acquisition on 31 December 2013 of the glaucoma treatment business from iScience Interventional Inc. iScience's lead product, the patented iTrack 250™ catheter, has strong clinical efficacy for the treatment of glaucoma with a procedure termed canaloplasty, which has advanced beyond treatment with SLT. Approximately 35,000 eyes have been treated with iTrack 250™ and this number continues to grow. Importantly, canaloplasty provides the business with a consumable, recurring revenue component to help smooth the peaks and troughs associated with the sales of capital equipment.

The growth in revenue in Asia of 21% over last year is a continuation of a trend that has been evident for the last 3 years. In particular, demand from China is pleasing. Investment in improved health is taking place and favourable population demographics mean that demand for our products will continue to grow. For example we note that cataract surgeries (a leading indicator of demand for our products) are currently conducted at a rate of approximately 1 surgery per 1000 people in China. In the USA there are approximately 14 cataract surgeries per 1000 people. This indicates the capacity for significant growth for our products in China.

In Japan sales in YEN grew by 3% and fell in Australian dollar by 3% with the devaluation of the YEN. In Europe our sales fell by 6% when adjusted for the impact of the devaluation of the Australian dollar. Notwithstanding this fall and the continued economic stasis in Europe, there was good take up in Europe of our new products which augurs well for the future.

Of particular importance to sales in USA and Europe in 2014 was the success of our new UltraQ Reflex™ product for treatment of vitreous "floaters". A common and annoying problem Ellex UltraQ Reflex™ has been optimised for their treatment. This is an exciting proprietary product with sales expected to grow well in the 2015 financial year on the strength of interest evident at the European Society of Cataract & Refractive Surgeons (ESCRS) in London in September 2014 where the product was on our booth.

In March 2014, after several years of research and development, our Ellex 2RT™ laser for treatment of early stage age related macular degeneration (AMD) was released for limited commercial sales to key opinion leaders and early adoptors in Australia, New Zealand and Europe. This followed the application, in February 2014, of a CE Mark for the product for



treatment of early AMD. Considerable interest was also entertained in 2RT™ at the ESCRS Conference in London. This was the first time 2RT™ was on a booth for sale.

While these early limited commercial sales take place the clinical trial being run by the Centre for Eye Research Australia (CERA) has continued. This is a multicentre, double blind, placebo controlled trial of AMD patients. Six sites have been established and approximately 185 patients have been recruited and interim results are expected in 2016.

During the current 2015 financial year we also expect a good contribution to revenue and earnings from the roll out of the Ellex Integre Pro™ photocoagulator range. For treatment of retinal disease, the features of the Integre Pro (multiple wavelength for more treatment options, special laser capability and excellent viewing optics) are being well received by our first customers.

In December 2013 the Company completed a successful placement of 10 million new ordinary shares to Australian Superannuation funds and high net worth individuals. This placement raised \$3 million and was used to acquire the canaloplasty business and to provide working capital.

In summary, the improved results in 2014 were obviously pleasing but our goal is to improve revenues again in 2015 and improve the profitability of the business overall.

A handwritten signature in black ink, appearing to read "V. Previn".

Victor Previn
Chairman

Dated: 10 October 2014